FindTrial
Sign In

Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy: A Multi-center, Retro- and Prospective, Observational, Real-World Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07310186
Enrollment
200
Registered
2025-12-30
Start date
2025-12-30
Completion date
2027-12-30
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Keywords

DLBCL, polatuzumab vedotin, Salvage Treatment

Brief summary

Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse. Currently, polatuzumab vedotin (pola) has been incorporated into DLBCL treatment (both for newly diagnosed and relapsed cases). However, for patients whose disease progresses after pola-containing regimens, the subsequent treatment options, efficacy, and survival outcomes remain unclear. Understanding these real-world scenarios is of great significance, as it can guide clinicians in developing better and more tailored treatment strategies for patients in the future. Therefore, we plan to conduct this real-world study titled Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy, aiming to obtain real-world data from the Chinese population.

Detailed description

This is a retro- and prospective, observational study

Interventions

OTHERobservational study

this is an observational study, we do not interfere with treatment strategies

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with DLBCL * Age ≥18 years * Prior treatment with a polatuzumab vedotin (pola)-containing regimen and confirmed disease progression (refractory/relapsed) after this therapy. * Availability of complete electronic medical records and ability to be contacted via telephone. * Full understanding of the study, voluntary participation, and willingness to sign the informed consent form.

Exclusion criteria

* Patients who have not received pola-based regimen treatment. * Incomplete electronic medical records or unreachable by telephone.

Design outcomes

Primary

MeasureTime frameDescription
complete response ratethrough study completion, an average of 2 yearsthe ratio of patients achieves complete response

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026